Risk factors for death by COVID-19, public hospital in Ciudad Juárez, México
##plugins.themes.themeEleven.article.main##
Palabras clave
COVID-19, Noncommunicable Diseases, Risk factors
Resumen
Background: On March 11, 2020, a COVID-19 pandemic was declared for a novel coronavirus named SARS-CoV-2 virus. This virus induces a severe inflammatory response, producing death in patients with COVID-19 disease, in México, in 2021, COVID-19 mortality becomes the second cause of death, with higher mortality in persons with previous conditions like chronic non-communicable diseases.
Objective: To identify the risk factors associated with deaths in patients diagnosed with COVID-19 from January 1 to December 31, 2021, hospitalized in a clinic of IMSS in Ciudad Juárez, Chihuahua, México.
Material and methods: An observational, cross-sectional, analytical study was used. Information from patients with confirmed diagnostic of COVID-19 was collected from the SINOLAVE platform and medical records. To identify risk factors, univariate and multivariate logistic regression was used.
Results: A total of 277 patients were included, 51.62% were male, the rest were female. Death from COVID-19 were associated with age (OR: 1.03; 95%CI: 1.01 - 1.06, p ≤ 0.001), chronic kidney disease (OR: 3.20; 95%CI: 1.58 - 6.48, p ≤ 0.001) chronic neurological diseases (OR: 5.27; 95%CI: 1.30 - 20.03, p ≤ 0.05), and chronic obstructive pulmonary diseases (OR: 12.24; 95%CI: 1.44 - 103.82, p ≤ 0.05); the proportion of death by sex were similar in the study
Conclusion: Age, chronic kidney disease, chronic neurological disease, and chronic obstructive pulmonary diseases were associated with death in patients with COVID-19. It’s important to prevent and control chronic non-communicable diseases; the distribution was similar in both sexes.
Referencias
1. Ignacio-Ibarra G, García-Lee MT, González-ávila AI, et al. A proposal for the management of covid-19-induced coagulopathy in adults. Gac Med Mex. 2021;157(2):209-14.
2. Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. Journal of the Royal Society of Medicine. SAGE Publications Ltd. 2021;114:428-42.
3. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19_ a systematic review and meta-analysis. Sci Rep. 2021;11(16144):1-13.
4. Organización Panamericana de la Salud / Organización Mundial de la Salud. Alerta Epidemiológica: Complicaciones y secuelas por COVID-19, 12 de agosto 2020. Washington D.C.: 2020.
5. World Health Organization. WHO. 2023. Coronavirus. Disponible en: https://www.who.int/es/health-topics/coronavirus#tab=tab_1
6. Núñez-Cortés R, Ortega-Palavecinos M, Soto-Carmona C, et al. Social determinants of health associated with severity and mortality in patients with COVID-19. Gac Med Mex. 2021 Mar 1;157(3):273-80.
7. Secretaría de Salud de México. 2022. INFORME INTEGRAL DE COVID-19 EN MÉXICO. México; 2022. Disponible en: http://epidemiologia.salud.gob.mx/gobmx/salud/documentos/covid19/Info-11-22-Int_COVID-19.pdf
8. Rashedi J, Mahdavi B, Asgharzadeh V, et al. Risk Factors for COVID-19. Infez Med. 2020;4:469-474.
9. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. The BMJ. 2020;368. doi: https://doi.org/10.1136/bmj.m1091
10. Solano-Ceh MÄ, Coronado-García AR, Salazar-Ventura J, et al. Factores de riesgo asociados a la mortalidad en pacientes COVID-19, en el estado de Oaxaca. Avances en Ciencia, Salud y Medicina. 2020;7(4):99-110. Disponible en: https://www.oaxaca.gob.mx/salud/revista-avance-en-ciencia-salud-y-medicina/
11. Gęca T, Wojtowicz K, Guzik P, et al. Increased Risk of COVID-19 in Patients with Diabetes Mellitus—Current Challenges in Pathophysiology, Treatment and Prevention. Int J Environ Res Public Health. 2022;19(11):6555. doi: 10.3390/ijerph19116555.
12. Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses. 2023;15(2):508. doi: 10.3390/v15020508.
13. Adir Y, Humbert M, Saliba W. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence. J Allergy Clin Immunol. 2021;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006.
14. Timberlake DT, Strothman K, Grayson MH. Asthma, severe acute respiratory syndrome coronavirus-2 and coronavirus disease 2019. Curr Opin Allergy Clin Immunol. 2021;21(2):182-187. doi: 10.1097/ACI.0000000000000720.
15. Franco PA, Jezler S, Cruz AA. Is asthma a risk factor for coronavirus disease-2019 worse outcomes? The answer is no, but... Curr Opin Allergy Clin Immunol. 2021;21(3):223-228. doi: 10.1097/ACI.0000000000000734.
16. Shafiee MA, Hosseini SF, Mortazavi M, et al. Anticoagulation therapy in COVID-19 patients with chronic kidney disease. J Res Med Sci. 2021;26:63. doi: 10.4103/jrms.JRMS_875_20.
17. Panimathi R, Gurusamy E, Mahalakshmi S, et al. Impact of COVID-19 on Renal Function: A Multivariate Analysis of Biochemical and Immunological Markers in Patients. Cureus. 2022;14(2):e22076. doi: 10.7759/cureus.22076. PMID: 35165642
18. Stefan N, Birkenfeld AL, Schulze MB et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16:341-342. Disponible en: https://doi.org/10.1038/s41574-020-0364-6
19. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020;28(7):1195-1199. doi: 10.1002/oby.22831.
20. Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol. 2021;268(4):1171-1178. doi: 10.1007/s00415-020-10131-y.
21. Meshkat S, Salimi A, Joshaghanian A, et al. Chronic neurological diseases and COVID-19: Associations and considerations. Transl Neurosci. 2020;11(1):294-301. doi: 10.1515/tnsci-2020-0141.
22. Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. Curr Opin Pulm Med. 2022;28(2):76-83. doi: 10.1097/MCP.0000000000000834.
23. Reddy RK, Charles WN, Sklavounos A, et al. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. J Med Virol. 2021;93(2):1045-1056. doi: 10.1002/jmv.26389.
24. Oliva-Sánchez PF, Vadillo-Ortega F, Bojalil-Parra R, et al. Factores de riesgo para complicaciones graves de COVID-19, comparando tres olas epidemiológicas. Un enfoque desde la atención primaria en México [Risk factors for COVID-19 severe complications comparing three major epidemiological waves: An approach from primary health care in Mexico]. Aten Primaria. 2022;54(11):102469. Spanish. doi: 10.1016/j.aprim.2022.102469.
25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. doi: 10.1016/S0140-6736(20)30606-1. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. doi: 10.1016/S0140-6736(20)30638-3. PMID: 32171076; PMCID: PMC7270627.
26. Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624. Erratum in: JAMA Cardiol. 2020 Aug 1;5(8):968. doi: 10.1001/jamacardio.2020.2338. PMID: 32324209; PMCID: PMC7180726.
27. Aguirre-Milachay E, León-Figueroa DA, Chumán-Sánchez M, et al. Factors associated with mortality in patients hospitalized for COVID-19 admitted to a tertiary hospital in Lambayeque, Peru, during the first wave of the pandemic. PLoS One. 2023;18(5): e0285133. doi: 10.1371/journal.pone.0285133.
28. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Ann Epidemiol. 2020;52:93-98. e2. doi: 10.1016/j.annepidem.2020.08.005.
29. ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87-94. doi: 10.1093/ndt/gfaa314.
##plugins.themes.themeEleven.article.sidebar##
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores conservan sus derechos de autor y otorgan a la Revista Médica del IMSS el derecho de primera publicación. Los artículos se distribuyen bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional, que permite su difusión siempre que se reconozca al autor y la fuente original.